Abstract
A series of novel 5-methyl-2,4-disubstitued-oxazole derivatives were synthesized and evaluated for their antitumor activities. The bioassay tests showed that 7-(5-methyl-2-(4-(R)phenyl)oxazol-4-yl)quinoline (R = trifluoromethyl, 2a; fluoro, 2b; chloro) and 2-(5-methyl-2-(4-(trifluoromethyl or fluoro)phenyl)oxazol-4-yl)pyrazine derivatives (4a and 4b) were highly effective against PC-3 cell with the IC50 values ranging from 1.2 to 2.0 μg/mL. 2-(2-(2,4-dichlorophenyl or 2,4-difluoro phenyl)-5-methyloxazol-4-yl)pyrazine (4e and 4f) were highly effective against A431 cell. The IC50 values of 4e and 4f against A431 cell were 2.0 and 1.6 μg/mL, respectively.
Keywords: Oxazole, Quoline, Synthese, Pyrazine, Antitumor activity
Letters in Drug Design & Discovery
Title: Novel 5-Methyl-2,4-Disubstitued-Oxazole Derivatives: Synthesis and Anticancer Activity
Volume: 7 Issue: 4
Author(s): Xin-Hua Liu, Hui-Feng Liu, Chun-Xiou Pan, Jin-Xin Li, Lin-Shan bai, Bao-An Song and Xiang-Feng Chu
Affiliation:
Keywords: Oxazole, Quoline, Synthese, Pyrazine, Antitumor activity
Abstract: A series of novel 5-methyl-2,4-disubstitued-oxazole derivatives were synthesized and evaluated for their antitumor activities. The bioassay tests showed that 7-(5-methyl-2-(4-(R)phenyl)oxazol-4-yl)quinoline (R = trifluoromethyl, 2a; fluoro, 2b; chloro) and 2-(5-methyl-2-(4-(trifluoromethyl or fluoro)phenyl)oxazol-4-yl)pyrazine derivatives (4a and 4b) were highly effective against PC-3 cell with the IC50 values ranging from 1.2 to 2.0 μg/mL. 2-(2-(2,4-dichlorophenyl or 2,4-difluoro phenyl)-5-methyloxazol-4-yl)pyrazine (4e and 4f) were highly effective against A431 cell. The IC50 values of 4e and 4f against A431 cell were 2.0 and 1.6 μg/mL, respectively.
Export Options
About this article
Cite this article as:
Liu Xin-Hua, Liu Hui-Feng, Pan Chun-Xiou, Li Jin-Xin, bai Lin-Shan, Song Bao-An and Chu Xiang-Feng, Novel 5-Methyl-2,4-Disubstitued-Oxazole Derivatives: Synthesis and Anticancer Activity, Letters in Drug Design & Discovery 2010; 7 (4) . https://dx.doi.org/10.2174/157018010790945878
DOI https://dx.doi.org/10.2174/157018010790945878 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Angiogenesis in the Treatment of Genito-Urinary Cancers: Last Updates
Current Angiogenesis (Discontinued) Src Tyrosine Kinase Inhibition Suppresses Lymphangiogenesis In Vitro and In Vivo
Current Cancer Drug Targets Phytoestrogens: Implications in Neurovascular Research
Current Neurovascular Research Review: The JAK/STAT Protein Activation – Role in Cancer Development and Targeted Therapy
Current Signal Transduction Therapy The Production of Solid Dosage Forms from Non-Degradable Polymers
Current Pharmaceutical Design Celastrol and Terpenes as Anti-Infective Agents
Anti-Infective Agents in Medicinal Chemistry Lactate Transporters and pH Regulation: Potential Therapeutic Targets in Glioblastomas
Current Cancer Drug Targets An Expanding Appreciation of the Role Chemokine Receptors Play in Cancer Progression
Current Pharmaceutical Design Therapeutic Perspectives of Inhibitors of Endocannabinoid Degradation
Current Drug Targets - CNS & Neurological Disorders Germinal and Somatic Trisomy 21 Mosaicism: How Common is it, What are the Implications for Individual Carriers and How Does it Come About?
Current Genomics Microarrays and the Genetic Analysis of Brain Tumors
Current Genomics MicroRNA-7 Regulates Insulin Signaling Pathway by Targeting IRS1, IRS2, and RAF1 Genes in Gestational Diabetes Mellitus
MicroRNA SUBJECT INDEX TO VOLUME 1
Current Drug Safety Molecular and Metabolic Imaging of Castration-Resistant Prostate Cancer: State of Art and Future Prospects
Current Molecular Medicine KCa3.1 Channels and Glioblastoma: In Vitro Studies
Current Neuropharmacology Rational Targeting of Peroxisome Proliferating Activated Receptor Subtypes
Current Medicinal Chemistry Looking out for Cancer Stem Cells’ Properties: The Value-Driving Role of CD44 for Personalized Medicines
Current Cancer Drug Targets Drug Conjugated Nanomedicine as Prodrug Carrier
Nanoscience & Nanotechnology-Asia HIF-1α and Calcium Signaling as Targets for Treatment of Prostate Cancer by Cardiac Glycosides
Current Cancer Drug Targets Proteasome Inhibitors Therapeutic Strategies for Cancer
Recent Patents on Anti-Cancer Drug Discovery